SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-137029
Filing Date
2022-05-02
Accepted
2022-05-02 17:20:25
Documents
7
Period of Report
2022-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A d325520ddef14a.htm DEF 14A 287366
2 GRAPHIC g325520g0503010232315.jpg GRAPHIC 5670
3 GRAPHIC g325520g0503010232518.jpg GRAPHIC 774
4 GRAPHIC g325520g32b41.jpg GRAPHIC 244331
5 GRAPHIC g325520g52b89.jpg GRAPHIC 2858
6 GRAPHIC g325520g72z22.jpg GRAPHIC 223137
7 GRAPHIC g325520s1.jpg GRAPHIC 896
  Complete submission text file 0001193125-22-137029.txt   947050
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

IRS No.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37524 | Film No.: 22883304
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences